Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Nuwellis ( (NUWE) ) has provided an announcement.
On September 30, 2025, Nuwellis, Inc. announced findings from the ULTRA-Peds registry, a multi-center observational study examining the real-world use of the Aquadex System in children with acute kidney injury (AKI), fluid overload, or congenital kidney failure.
The most recent analyst rating on (NUWE) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Nuwellis stock, see the NUWE Stock Forecast page.
Spark’s Take on NUWE Stock
According to Spark, TipRanks’ AI Analyst, NUWE is a Neutral.
Nuwellis’ overall stock score is primarily impacted by its financial challenges, including ongoing losses and negative cash flows. Technical indicators suggest bearish momentum, and valuation metrics are weak due to a negative P/E ratio. While recent corporate events and strategic initiatives offer some promise, the immediate financial outlook remains concerning.
To see Spark’s full report on NUWE stock, click here.
More about Nuwellis
Average Trading Volume: 909,125
Technical Sentiment Signal: Sell
Current Market Cap: $3.19M
For detailed information about NUWE stock, go to TipRanks’ Stock Analysis page.